TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 06, 2024 07:00 ET
|
TScan Therapeutics, Inc.
Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are...
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
February 26, 2024 07:00 ET
|
TScan Therapeutics, Inc.
All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated...
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
February 14, 2024 07:00 ET
|
TScan Therapeutics, Inc.
TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing the...
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
February 06, 2024 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
January 29, 2024 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
January 18, 2024 07:00 ET
|
TScan Therapeutics, Inc.
Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan...
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
January 04, 2024 07:00 ET
|
TScan Therapeutics, Inc.
Reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting Clearance of INDs for four TCR-Ts, including a TCR-T for PRAME, in support...
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
December 09, 2023 12:00 ET
|
TScan Therapeutics, Inc.
No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical...
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
December 07, 2023 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...